|
|
|
|
|
|
|
|
|
11.08.25 - 13:33
|
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress (Business Wire)
|
|
|
Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones
BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO
Regulatory alignment secured for Phase 3 trial initiation, expected to commence in Q4 2025
August 27th virtual stakeholder meeting set for a detailed discussion on progress
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a next-generation, multifunctional, Fc enhanced, CTLA-4 antibody and BAL is a proprietary PD-1 antibody; together they are designed to trigger robust and durable immu...
|
|
|
|
|
31.07.25 - 13:36
|
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive update on the global botensilimab (BOT) and balstilimab (BAL) development program.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery,...
|
|
|
|
|
|
|
|
|
|
|
10.06.25 - 19:33
|
Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Tuesday, June 17, 2025
Time: 10:30 a.m. ET
A live webcast and replay will be accessible on the Company's website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2025.
Voting Information:
Shareholders of Agenus as of the April 24th, 2025, record date can vote. Alliance Advisors, Agenus's proxy solicit...
|
|
|
|
|
04.06.25 - 03:54
|
Agenus und Zydus Lifesciences gehen strategische Zusammenarbeit im Wert von 141 Millionen US-Dollar ein, um BOT/BAL voranzutreiben und die Biologika-Produktion von Zydus in den USA auszuweiten (Business Wire)
|
|
|
75 Mio. US-Dollar Vorauszahlung an Agenus für die Übertragung von Produktionsanlagen
50 Mio. US-Dollar bedingte Zahlungen an Agenus
Exklusive Lizenz für BOT/BAL in Indien und Sri Lanka
16 Mio. US-Dollar Kapitalbeteiligung zu 7,50 US-Dollar pro Aktie
LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. ( Nasdaq: AGEN), ein führendes Unternehmen im Bereich der immunonkologischen Innovation, gab heute bekannt, dass es endgültige Partnerschaftsvereinbarungen mit Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), einschließlich ihrer Tochtergesellschaften/verbundenen Unternehmen, im Folgenden als „Zydus“ bezeichnet, um die klinische Entwicklung zu beschleunigen, die weltweite Produktion auszuweiten und den Zugang von Patienten zu Botensilimab und Balstilimab (BOT/BAL) zu verbessern.
Die strategische Zusammenarbeit umfasst den Austausch der hochmodernen CMC-Einrichtungen für Biologika von Agenus in Emeryville, Kalifornien, und Berkeley, Kalifornien, gegen eine Vorabzahlung in Höhe von 75 Millionen US-Doll...
|
|
|
|
|
|
|
03.06.25 - 13:55
|
XFRA: AJ8: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
AGENUS INC. DL-,01 AJ8 US00847G8042
AB/FROM ONWARDS 03.06.2025 13:48 CET...
|
|
|
03.06.25 - 13:25
|
XFRA: AJ8: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
AGENUS INC. DL-,01 AJ8 US00847G8042 BAW/UFN...
|
|
|
|
|
03.06.25 - 13:03
|
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus′ Biologics Manufacturing in the US (Business Wire)
|
|
|
$75M upfront payment to Agenus for the transfer of manufacturing assets
$50M of contingent payments to Agenus
Exclusive license for BOT/BAL in India and Sri Lanka
$16M equity investment at $7.50 per share
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL).
The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics CMC facilities in Emeryville, CA and Berkeley, CA for upfront consideration of $75M; Agenus to receive up to an additional $50M in contingent payments triggered by BOT/BAL production orders. Zydus, an India-based multinational pharmaceutical company with over 27,000 employees and operations in...
|
|
|
30.05.25 - 13:33
|
Agenus Presents New Data at ASCO Highlighting Botensilimab′s Immune Activation in MSS Colorectal Cancer (Business Wire)
|
|
|
Study shows botensilimab “switches on” the body's own T-cells to attack a common, treatment-resistant form of colorectal cancerLEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approximately 85-95% of all colorectal cancers. T cells are key immune cells capable of recognizing and attacking cancer cells. Activating these typically 'cold' tumors and driving a strong T cell response suggests that botensilimab has the potential to overcome resistance and improve patient outcomes.
The research was led by Dr. Gertjan Rasschaert of Leuven University Hospitals in collabor...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
